KB407 (Nebulization)
Phase 1Biologic
KB407 (Nebulization) is one of 43 biologic programs targeting Cystic Fibrosis. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
107 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Ibsrela
AArdelyx
Phase 3
Zyvox
PfizerPhase 2
Mycobutin
PfizerPhase 2
HSK31858
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Tygacil
PPrism Pharmaceuticals
Phase 2
Amoxil
GGlobal Antibiotics Research and Development Partnership
Phase 2
ELX/TEZ/IVA
Vertex PharmaceuticalsPhase 3
Trimethoprim-Sulfamethoxazole
AstellasPhase 2
Trikafta
NNottingham University Hospitals NHS Trust
Phase 3
VNZ/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KB407 (Nebulization). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- KKrystal Biotech, Inc.